GSK Moves Closer To Priority Review Voucher As US Panel Backs Malaria Drug Tafenoquine
Executive Summary
GlaxoSmithKline's user fee date is July 22, four days before advisory committee review of 60 Degrees’ separate application for the compound.
You may also be interested in...
Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys
The latest drug development news and highlights from our US FDA Performance Tracker.
60 Degrees’ Arakoda Gets US FDA Panel Nod For Malaria Prophylaxis
Postmarketing studies are needed to assess tafenoquine’s efficacy in children, older adults and heavier individuals, and to answer questions about psychiatric safety and other adverse events, advisory committee says.